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On December 15, 2008, former Congressman 
Dick Gephardt facilitated a program that featured 
keynote speaker Governor Edward G. Rendell 
to discuss the future of medical innovation in 
the United States. The discussion focused, in 
particular, on the greater Philadelphia area in 
the context of the current economic downturn. 
In addition to the keynote, two expert panels 
highlighted obstacles to innovation as well as 
potential solutions. Panelists included:
•   Dennis M. “Mickey” Flynn, President of 
Pennsylvania BIO 
•   Glen N. Gaulton, PhD, Executive Vice Dean, 
Chief Scientific Officer at The University of 
Pennsylvania School of Medicine 
•   Brenda Gavin, DVM, MBA, Founding Partner 
of Quaker BioVentures 
•   Paul Howard, PhD, Senior Fellow and Director 
of the Center for Medical Progress at the 
Manhattan Institute for Policy Research 
•   Russel Kaufman, MD, President and CEO of 
the Wistar Institute 
•   Alan Leshner, PhD, CEO of the American 
Association for the Advancement of Science 
•   Joseph M. Mahady, President of Wyeth 
Pharmaceuticals and Senior Vice President  
at Wyeth 
•   Thomas Morr, President and CEO of Select 
Greater Philadelphia 
•   David B. Nash, MD, MBA, Dean of the 
Jefferson School of Population Health at  
Thomas Jefferson University 
•   Barbara S. Schilberg, Managing Director and 
Chief Executive Officer of BioAdvance 
•   The Honorable Joe Sestak (D-PA), U.S. House 
of Representatives 
•   George Wohlreich, MD, Director and CEO of 
the College of Physicians of Philadelphia 
The Greater Philadelphia area is a hub for medical 
innovation activities, with a strong biotechnology 
sector and numerous academic institutions  
with nationally recognized programs in the  
life sciences. According to a 2005 Milken  
Institute study1, the medical innovation industry 
in Greater Philadelphia encompasses 11.4 percent 
of all employment in the region, 12.8 percent  
of total earnings, and 7.1 percent of gross  
metro product. 
Panelists drew attention to several key  
issues the region faces in capitalizing on these  
resources, with a focus on research and 
development, financing, and education.  
With respect to research and development, 
effective technology transfer and translational 
research will allow medical innovation to  
evolve along the continuum from basic science 
research to clinical care at the bedside. In  
order for this to occur, partnerships between 
academia and industry are essential. Funding 
challenges include aligning incentives for  
research and development, incentives for 
investigators to pursue basic science research,  
and defining the roles of public and private 
funding sources. Finally, panelists indicated  
that high quality education in the sciences 
must begin in elementary school and continue 
throughout higher education. Graduate  
programs in the sciences must be able to  
recruit young investigators and retain them 
following graduation.  
The event was co-hosted by America’s 
biopharmaceutical companies, Pennsylvania BIO, 
BioAdvance and Select Greater Philadelphia.   
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